Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder in Canada
2014
This article, published in BMC Psychiatry, presents a decision tree combined with a Markov model that estimates the cost-effectiveness of asenapine compared with olanzapine in the treatment of bipolar disorder in Canada. The decision tree part of the model takes into account the occurrence of extrapyramidal symptoms, the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model part takes into account the long-term metabolic complications including diabetes, hypertension, coronary heart diseases, and stroke. Analyses are conducted from both the Canadian Ministry of Health and the societal perspective over a five-year time horizon with yearly cycles.
Results indicate that asenapine is associated with lower costs and more quality-adjusted life years in the treatment of bipolar disorder as compared with olanzapine from both perspectives. Probabilistic sensitivity analyses show that asenapine remains a dominant strategy in 99.2% of the simulations, in both perspectives.
Based on these findings the authors conclude that asenapine is a cost-effective strategy compared to olanzapine in the treatment of BPD in Canada.
Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder in Canada
Source:
Lachaine J, Beauchemin C, Mathurin K et al. Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder in Canada. BMC Psychiatry 2014; 14 (16). https://doi.org/10.1186/1471-244X-14-16